Apellis Pharmaceuticals, Inc. (APLS)

Market Cap	2.51B
Revenue (ttm)	781.37M
Net Income (ttm)	-197.88M
Shares Out	125.52M
EPS (ttm)	-1.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,487,906
Open	22.57
Previous Close	22.52
Day's Range	19.76 - 23.10
52-Week Range	19.76 - 57.85
Beta	0.84
Analysts	Buy
Price Target	45.59 (+128.29%)
Earnings Date	May 6, 2025

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem ce...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 9, 2017
• Employees: 710
• Stock Exchange: NASDAQ
• Ticker Symbol: APLS
• Website: https://apellis.com

Financial Performance

In 2024, Apellis Pharmaceuticals's revenue was $781.37 million, an increase of 97.02% compared to the previous year's $396.59 million. Losses were -$197.88 million, -62.57% less than in 2023.

Analyst Forecast

According to 18 analysts, the average rating for APLS stock is "Buy." The 12-month stock price forecast is $45.59, which is an increase of 128.29% from the latest price.

Price Target

$45.59

(128.29% upside)

Analyst Consensus: Buy